


First-in-Class Antibody Therapeutics
Anti-PAUF for Pancreatic Cancer

PBP1510




PRESTIGE BIOPHARMA
Innovative Discovery Center

Conquering Pancreatic Cancer via Novel Therapeutic Antibody

Ulenistamab PBP1510

World's first targeted antibody therapy for pancreatic cancer



Treating Novel Antibody Drug to Pancreatic Cancer

PBP1510 is a First-in-Class antibody drug developed to target pancreatic adenocarcinoma up-regulated factor (PAUF), a molecule that promotes cancer progression and metastasis via multiple pathways

Targeting Tumor Micro-environment

PBP1510 acts in tumor microenvironment (TME) to restore the antitumor immunity suppressed by PAUF and to block the proliferation and metastasis of cancer cells



•Orphan Drug Designation Grand Slam



•FDA Fast Track Designation




PBP 1510 (INN: Ulenistamab)

| | | | |
|------------|-----------------------------------|-------------------|-----------------------------|
| Indication | Pancreatic Cancer, Ovarian Cancer | Target | PAUF |
| Category | Monoclonal Antibody | Development Stage | Phase 1/2a (EU, USA & Asia) |


■ PBP1510: Mechanism of Action

Ulenistamab blocks PAUF and acts as a tumor micro-environment modulator




■ Efficacy

Combination of ulenistamab and gemcitabine demonstrates enhanced efficacy and survival



■ Approval Pathway

Phase 1/2a in pancreatic cancer (PAUF-I Study) ongoing in EU, USA and Asia




Pipeline Highlights

First-in-Class Antibody Therapeutics

PBP1510

Anti-PAUF, Ulenistamab



FDA ORPHAN DRUG DESIGNATION FDA FAST TRACK DESIGNATION

First-in-Class Antibody PBP1510 (Ulenistamab)

- Development stage : Phase 1/2a (EU, USA & Asia)
- Indication : Pancreatic cancer, Ovarian cancer
- Orphan Drug Designation by FDA, EMA, MFDS
- Fast Track Designation by FDA



First-in-Class Antibody PBP1710 (Anti-CTHRC1)

- Development stage : Preclinical
- Indication : Solid tumors
- Patent registered in Korea in January 2023

| Category | Pipeline | Indication | Development Stage |
|-------------------------|-----------------------|-----------------------------------|-----------------------|
| First-in-class | Ulenistamab (PBP1510) | Pancreatic cancer, Ovarian cancer | Clinical (Phase 1/2a) |
| | PBP1710 | Solid tumor | Preclinical |
| | IDC111 | Solid tumor | Basic Research |
| Bispecific Antibody | IDC001 | Solid tumor | Basic Research |
| | IDC002 | Solid tumor | Basic Research |
| | IDC003 | Solid tumor | Basic Research |
| | IDC005 | Solid tumor | Discovery |
| | IDC007 | Critical immune disorders | Discovery |
| | IDC008 | Solid tumor | Discovery |
| | IDC009 | Solid tumor | Discovery |
| | IDC010 | Immune disease | Discovery |
| Novel Concept Antibody | IDC331 | Solid tumor | Discovery |
| | IDC332 | Solid tumor | Discovery |
| | IDC333 | Solid tumor | Discovery |
| | IDC334 | Solid tumor | Discovery |
| Antibody Drug Conjugate | IDC441 | Solid tumor | Basic Research |



Innovative Discovery Center (IDC)

Prestige Biopharma IDC Co., Ltd.
 2776-8, Myeongji-dong, Gangseo-gu,
 Busan 618-814, South Korea
 Tel: +85 51 580 8000
 Email: idc@prestigebio.com

a member of  CANCER MOONSHOT

PBPUL010524EN



PRESTIGEBIOPHARMA



Youtube



Publication